Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors

Pediatric Hematology and Oncology
Aynur OguzNilufer Eldes

Abstract

A prospective, open-label, randomized, comparative study in pediatric cancer patients was conducted to evaluate the efficacy and safety of cefepime and meropenem in the empiric therapy of febrile neutropenic patients. Febrile episodes were classified as microbiologically documented infection, clinical documented infection, or fever of unknown origin. Clinical response to therapy was classified as success or failure. In this period 37 children with solid tumors including lymphoma, 25 males, 12 females, had neutropenia on 65 occasions. Microbiologically documented infections occurred in 21 episodes (32.31%). Frequency of positive bacteria isolated was higher than gram-negative bacteria. There was no infection-related death. There were no statistical differences between the cefepime and meropenem groups for duration of fever or neutropenia, response rate, and necessity for modification. Cefepime appears to be as effective and safe as meropenem for empiric treatment of febrile episodes in neutropenic pediatric cancer patients.

References

Mar 1, 1984·The American Journal of Medicine·P A PizzoK J Robichaud
Nov 1, 1993·The Journal of Antimicrobial Chemotherapy·P EggimannT Calandra
Nov 1, 1993·The Journal of Antimicrobial Chemotherapy·C ThornsberryT Rich
Jul 1, 1995·The Journal of Antimicrobial Chemotherapy·J R Edwards
Oct 6, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W T HughesL S Young
Oct 28, 1998·Scandinavian Journal of Infectious Diseases·R LindbladI Turesson
Mar 31, 2000·Medical and Pediatric Oncology·P ChastagnerD Sommelet
Apr 18, 2001·Chemotherapy·B M JándulaJ Sierra
Feb 19, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Walter T HughesLowell S Young

❮ Previous
Next ❯

Citations

Jan 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of Americaa
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America
Feb 13, 2016·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Masaki FujitaUNKNOWN Lung Oncology Group in Kyushu (LOGIK)
Sep 18, 2010·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·X Durrmeyer, R Cohen
Sep 12, 2009·Pediatrics International : Official Journal of the Japan Pediatric Society·Sema VuralRejin Kebudi
May 4, 2010·The Journal of Pediatrics·Elisabeth E AddersonJames M Hoffman
Mar 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paula D RobinsonLillian Sung
Dec 17, 2011·The Pediatric Infectious Disease Journal·Arif ManjiLillian Sung
Nov 12, 2010·The Cochrane Database of Systematic Reviews·Mical PaulLeonard Leibovici
Dec 6, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Arif ManjiLillian Sung
Mar 22, 2018·Frontiers in Pediatrics·Saber JanMaria Gutierrez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.